EUCTR2008-008444-25-EE进行中（未招募）不适用
A Phase II, open-label trial with TMC207 as part of a multi-drug resistant tuberculosis (MDR-TB) treatment regimen in subjects with sputum smear-positive pulmonary infection with MDR-TB.
Janssen Infectious Diseases BVBA0 个研究点目标入组 225 人开始时间: 2009年7月29日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects aged 18 years or older. Females may participate if they are of nonchildbearing potential, if they are using effective birth control methods and are willing to continue practicing birth control methods as outlined in Protocol Section 5.2.4 throughout MDR-TB treatment, or if they are nonheterosexually active or willing to practice sexual abstinence throughout MDR-TB treatment.
- •2. Confirmed pulmonary MDR-TB infection, which is defined as infection by a strain of M. tuberculosis resistant to at least both RMP and INH by previous screening from a TB treatment facility or by use of a rapid screen test within the preceding 6 months. Subjects infected with XDR-TB are also allowed to enter the trial if they have at least 3 TB drugs in their BR to which they are likely to be susceptible.
- •3. Positive for acid-fast bacilli (AFB) on direct smear examination of expectorated sputum specimen (= 1+ smear-positive) or sputum culture positive for Mycobacterium tuberculosis within the preceding 6 months.
- •4. Documented HIV-negative or -positive status at screening or within 1 month prior to trial start (via enzyme-linked immunosorbent assay [ELISA] and/or Western Blot). Note: HIV-positive subjects are eligible, provided they meet the requirements and are willing to follow the ARV treatment procedures as outlined in Section 5.2.4 and they are not using disallowed (ARV) medication as described in Section 5.3.11.
- •5. Subjects having signed the ICF voluntarily before the first trial-related activity.
- •6. Subjects who can comply with protocol requirements.
- •7. Subjects who agree to comply with the NTP treatment guidelines.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •1. Subjects having a known or suspected hypersensitivity or serious adverse reaction to TMC207.
- •2. Subjects using disallowed concomitant therapy as specified in Protocol Section 5.3.11.
- •3. Subjects having a current or past history of alcohol and/or drug use that, in the investigator's opinion, would compromise the subject's safety or compliance to the study protocol procedures.
- •4. HIV infected subjects having a CD4+ count < 250 cells/µL.
- •5. Subjects with significant cardiac arrhythmia requiring medication.
- •6. Subjects with complicated or severe extrapulmonary manifestations of TB, including central nervous system infection.
- •7. Having participated in other clinical studies with investigational agents, within 8 weeks prior to trial start.
- •8. Presence of any concomitant severe illness or rapidly deteriorating health condition, including immune deficiency that would make implementation of the protocol or interpretation of the study results difficult or otherwise make the subject a poor candidate for a clinical trial.
- •9. Subjects with the following QT/QTc interval characteristics at screening:
- •a. A marked prolongation of QT/QTc interval, e.g., confirmed demonstration of QTcF (Fridericia correction) interval > 450 ms at screening;
- •b. A history of additional risk factors for Torsade de Pointes, e.g., heart failure, hypokalemia, family history of Long QT Syndrome;
- •c. The use of concomitant medications that prolong the QT/QTc interval listed as disallowed medication in Protocol Section 5.3.11;
- •d. Pathological Q-waves (defined as > 40 ms or depth > 0.4-0.5 mV);
- •e. Evidence of ventricular pre-excitation;
- •f. ECG evidence of complete or incomplete left bundle branch block or right bundle branch block;
- •g. Evidence of second or third degree heart block;
- •h. Intraventricular conduction delay with QRS duration > 120 ms;
- •i. Bradycardia as defined by sinus rate < 50 bpm.
- •10. Subjects with the following toxicities at screening as defined by the enhanced Division of Microbiology and Infectious Diseases (DMID) adult toxicity table (November 2007):
- •- Creatinine grade 2 or greater (> 1.5 times upper limit of normal [ULN]);
- •- Lipase grade 3 or greater (> 2.0 x ULN);
- •- Hemoglobin grade 4 (< 6.5 g/dL) except after discussion with the Medical Leader;
- •- Aspartate aminotransferase (AST) grade 4 (> 8.0 x ULN) to be excluded, grade 3 (= 3.0 x ULN) must be discussed with Medical Leader;
- •- Alanine aminotransferase (ALT) grade 4 (> 8.0 x ULN) to be excluded, grade 3 (= 3.0 x ULN) must be discussed with Medical Leader;
- •- Alkaline phosphatase (ALP) grade 4 (> 8.0 x ULN) to be excluded, grade 3 (= 3.0 x ULN) must be discussed with Medical Leader;
- •- Total bilirubin grade 3 or greater (> 2.00 x ULN, or > 1.50 x ULN when accompanied by any increase in other liver function test) to be excluded, grade 2 (> 1.50 x ULN, or > 1.25 x ULN when accompanied by any increase in other liver function test) must be discussed with the Medical Leader;
- •11. Women who are pregnant or breastfeeding.
- •12. Subjects who have previously received treatment with TMC207 as part of a clinical trial.
- •13. Subjects having AIDS defining illnesses other than TB, or showing severe symptoms of HIV infection that would make the subject a poor candidate for participation in the trial.
- •14. Subjects who, upon the evaluation of their pulmonary disease, will require surgical procedure for management of their TB infection within the 24-week treatment period with TMC207.
研究者
相似试验
进行中（未招募）
不适用
Safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen in MDR-TB (Multi-drug Resistant Tuberculosis).Sputum smear-positive pulmonary multi-drug resistant tuberculosisMedDRA version: 14.1Level: PTClassification code 10044755Term: TuberculosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-008444-25-LVJanssen Infectious Diseases BVBA225
已完成
不适用
Safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen in MDR-TB (Multi-drug Resistant Tuberculosis).PER-128-09Janssen Infectious Diseases - Diagnostics BVBA,19
已完成
2 期
To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.TuberculosisNCT00910871Janssen Infectious Diseases BVBA241
已完成
2 期
TMC114-TiDP29-C228: Study of antiviral activity of DRV in combination with low dose ritonavir in the treatment experienced HIV-1 infected childerns from 3 years to < 6 years of age.CTRI/2009/091/000374Tibotec Pharmaceuticals, EastGate Village, Eastgate, Little Island, CO Cork, Ireland24
进行中（未招募）
不适用
A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve HIV-1 infected subjects - ECHOHIV infectionMedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2007-002646-38-SETibotec Pharmaceuticals680